Uncategorized

Posted by | September 17, 2020
Praxis Precision Medicines Expands Leadership Team to Advance its Pipeline for CNS Disorders

- - - - - - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for people with central nervous system...

Continue Reading
Posted by | July 28, 2020
Praxis Precision Medicines Announces $110 Million Financing

- - - - - - Participation from top-tier healthcare investors recognizes momentum across breadth of its CNS therapeutics portfolio - - - - - - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Praxis Precision...

Continue Reading
Posted by | June 11, 2020
Praxis Precision Medicines Promotes Business Leader Stuart Chaffee to Chief Financial Officer

- - - - - - Cambridge, Mass., Wednesday, June 11, 2020– Praxis Precision Medicines, a clinical-stage, genetic neuroscience company, today announced the promotion of Stuart Chaffee, Ph.D., to chief...

Continue Reading
Posted by | May 4, 2020
Praxis Precision Medicines Launches with over $100 Million to Advance Pipeline of High Impact Therapies for Brain Disorders

- - - - - - Phase 2 Pipeline for Psychiatric Disorders, Movement Disorders and Genetic Epilepsies Founded by World Leaders in Neuroscience and Human Genetics Research, Kiran Reddy, M.D.,...

Continue Reading